InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase III registrational trial of the Company's novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-488, for the treatment of moderate-to-severe plaque psoriasis in China.
This is a multicenter, randomized, double-blinded, placebo-controlled Phase III clinical study, designed to evaluate the efficacy and safety of ICP-488 monotherapy in adult patients with moderate-to-severe plaque psoriasis.
ICP-488 is an oral, potent and selective TYK2 allosteric inhibitor. By binding to the JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory cytokines, thereby inhibiting the pathological processes of autoimmune and inflammatory diseases.
According to the data presented at the Late-breaking Research session of the 2025 American Academy of Dermatology (AAD) Annual Meeting, the Phase II study results demonstrated that ICP-488 is highly effective in treating psoriasis at both 6 mg QD and 9 mg QD doses. Moreover, ICP-488 exhibited favorable safety and tolerability profiles, reinforcing its potential as a valuable treatment option for patients with moderate-to-severe psoriasis.
Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare, said, 'Psoriasis severely affects patients' quality of life and requires safer, more effective oral medications. We are pleased that ICP-488 has received recognition at international academic conferences for its promising clinical data, and we will accelerate the Phase III clinical program. In addition to psoriasis, InnoCare is rapidly advancing several Phase III registration trials in the field of autoimmune diseases. We look forward to bringing our innovative therapies to more patients around the world.'
Recent data indicates that approximately 8.66 million people in China are currently living with psoriasis 1, and this number is on the rise 2. Existing treatment options do not fully address the needs of psoriasis patients, with particularly high demand for novel, oral medications.
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
InnoCare Forward-looking Statements
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
1 Epidemiological Burden Analysis of Psoriasis in China Based on the Global Burden of Disease (GBD) Big Data [J]. Chinese Journal of Dermatovenereology, 2021.
2 2021. Progress in Epidemiological Investigation of Psoriasis, Journal of Diagnostics Concepts & Practice. 2021.
Chunhua Lu
86-10-66609879
KEYWORD: CHINA ASIA PACIFIC
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY
SOURCE: InnoCare Pharma
Copyright Business Wire 2025.
PUB: 03/20/2025 07:39 AM/DISC: 03/20/2025 07:40 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
14 hours ago
- Health Line
Why Is My Hair Falling Out?
Key takeaways Normal hair shedding is up to 100 hairs per day, but excessive shedding may indicate telogen effluvium, a common hair loss condition. Hair loss can be caused by multiple factors, including hormonal changes, thyroid disorders, stress, medications, nutrient deficiencies, and autoimmune conditions like lupus. Treatment options include medications like finasteride and minoxidil, topical creams, steroid injections, platelet-rich plasma (PRP) therapy, hair transplants, scalp micropigmentation, and laser therapy. You can lose hair due to factors like nutritional deficiencies and stress. Hair loss can also occur as a side effect of medication or if you have underlying health conditions, such as lupus. Finding hair in your brush or on your pillow is normal. According to the American Academy of Dermatology, people naturally shed up to 100 hairs per day. However, if you experience excessive hair shedding, you may have telogen effluvium, a common hair loss condition. Keep reading to learn more about what's causing your hair to fall out and how to treat it. What are the most common types of hair loss? There are three common types of hair loss, some of which may affect hair at different stages of the growing cycle: Telogen effluvium: This type of hair loss is characterized by significant shedding. It affects hair in the resting phase, known as telogen. Around 15% of your hair is telogen, while 85% is androgen. Androgenic alopecia: This genetic type of hair loss affects hair in the growing stage, known as androgen. It's also known as male or female pattern baldness and affects nearly 1 in 2 people. Hormonal changes Several hormonal changes may lead to hair loss. For instance, changes in estrogen, progesterone, and prolactin following childbirth or during menopause may trigger hair loss. Similarly, changes in the male hormones testosterone and dihydrotestosterone could also trigger hair loss. Thyroid disorders Research suggests that thyroid disorders may play a key role in hair shedding and hair loss. Hyperthyroidism is a condition in which the thyroid gland is overactive, producing too many thyroid hormones. Hypothyroidism is when the thyroid gland doesn't produce enough thyroid hormones. According to the British Thyroid Foundation, your hair may take a few months to start growing back once you start treatment for your thyroid disorder. Learn more about the link between thyroid disorders and hair loss. Stress Physical and psychological stress have been closely associated with hair loss. Acute physical stressors may include: serious illness surgery fever blood loss childbirth The causes of physical stress are often temporary, and the hair loss subsides as the body heals. Chronic psychological stress and anxiety may increase the speed of your hair cycle, leading to more hair falling out. Several lifestyle changes could help you relieve stress, such as: exercising for at least 150 minutes weekly eating a well-balanced diet meditating speaking with a friend, family member, or therapist Medications Medications can come with many side effects, including hair loss. Chemotherapy is the most well-known cause, but other medications that may cause hair shedding include: retinoids beta-blockers anticonvulsants antidepressants anticoagulants some oral contraceptives Speak with a healthcare professional if you take any of these medications and experience hair loss. They could review your treatment plan and recommend an alternative medication or modify your current dosage. Learn more about medications that can cause hair loss. Other medical conditions Many other medical conditions can lead to hair shedding and hair loss, including: renal failure liver disease Crohn's disease diabetes psoriasis dermatitis ringworm of the scalp folliculitis Treatment Hair loss has been associated with lower self-esteem, body image issues, and a lower quality of life. However, it's important to note that you're not alone in experiencing hair loss. Several treatments could also help you slow the shedding or even promote hair growth. These may include: medications, such as finasteride and minoxidil topical creams steroid injections platelet-rich plasma (PRP) therapy hair transplant scalp micropigmentation laser therapy Some natural remedies like coconut oil, aloe vera, and fish oil may also help. Frequently asked questions Why is my hair falling out so much all of a sudden? Your hair may suddenly be falling out if you recently experienced stress caused by hormonal changes, fever, surgery, childbirth, and certain health conditions. You may also experience hair loss if you just started taking a new medication, such as beta-blockers and anticonvulsants. How do I know if I'm losing too much hair? How much hair you lose is subjective. If you notice a lot of hair around your home or new bald spots, thinning hair, or hair that pulls easily when you examine your scalp, speak with a doctor. They could provide a proper diagnosis and treatment plan for you. Why does my hair fall out in the shower? Hair loss during your shower is normal because you're adding stress to your scalp by pulling your hair. However, sudden, excessive hair loss may be caused by an underlying health condition, stress, or taking certain medications.
Yahoo
2 days ago
- Yahoo
Wealth Minerals' Participation in Successful Consortium License Permitting Bid
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2025) - Wealth Minerals Ltd. (TSXV: WML) (OTCQB: WMLLF) (SSE: WMLCL) (FSE: EJZN) (the "Company" or "Wealth") announces that a Consortium to develop the Quillagua Este Salar in the Antofagasta Region, Chile, of which Wealth is a member, has successfully submitted a CEOL (Special Lithium Operating Contract) application under the fast-track process announced by the Chilean Government in September 2024 (see press release of September 30, 2024) and expanded in December 2024. The application was admitted by the Chile licensing authorities due to the application Consortium: having more than 80% of the applicable polygon, demonstrating relevant mining experience, and demonstrating financial capacity to fund a mining project. For reference about the CEOL fast-track process, please see press release of April 23, 2025. Next steps, as per the CEOL process, are the conclusion of Indigenous consultations, negotiations with the State organs as to specific operating terms and a Presidential decree establishing the CEOL based on the application. Wealth participated with three other local partners in a joint bid (the "Consortium") to extract lithium from the Quillagua Este Salar and is to provide strategic advice and know-how to the Consortium from its long operating experience in Chile. Wealth has a 3% stake in the Consortium. The CEOL application calls for lithium production from the Quillagua Este Salar, although presently the Quillagua Este Salar lithium project of the Consortium does not have an established resource or feasibility study. Regarding the Consortium's success, Henk van Alphen, CEO of Wealth Minerals Ltd., said, "While Wealth's stake in this endeavor is modest, this news does show that the Chilean regulatory regime can be successfully navigated, while also demonstrating that the Chilean authorities support the development of new lithium projects fully privately owned. Our success working with a group to make this CEOL application further underscores our commitment to permitting our Kuska project, which is only 120 km away to the northeast of the Quillagua Este Salar." About Wealth Minerals Ltd. Wealth is a mineral resource company with interests in Canada and Chile. The Company's focus is the acquisition and development of lithium projects in South America. The Company opportunistically advances battery metal projects where it has a peer advantage in project selection and initial evaluation. Lithium market dynamics and a rapidly increasing metal price are the result of profound structural issues with the industry meeting anticipated future demand. Wealth is positioning itself to be a major beneficiary of this future mismatch of supply and demand. In parallel with lithium market dynamics, Wealth believes other battery metals will benefit from similar industry trends. For further details on the Company readers are referred to the Company's website ( and its Canadian regulatory filings on SEDAR+ at On Behalf of the Board of Directors of WEALTH MINERALS LTD. "Hendrik van Alphen"Hendrik van AlphenChief Executive Officer For further information, please contact:Marla Ritchie, Michael Pound or Henk van AlphenPhone: 604-331-0096 or 604-638-3886 For all Investor Relations inquiries, please contact:John LiviakisLiviakis Financial Communications 415-389-4670 For all Public Relations inquiries, please contact:Nancy ThompsonVorticom, 212-532-2208 | Mobile: 917-371-4053 Follow Us: Facebook - - - Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and US securities legislation. All statements, other than statements of historical fact, included herein including, without limitation, statements regarding the anticipated content, commencement, timing and cost of exploration programs, anticipated exploration program results, the discovery and delineation of mineral deposits/resources/reserves, the Company's expectation that it will be able to enter into agreements to acquire interests in additional mineral projects, and the anticipated business plans and timing of future activities of the Company, are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking statements as a result of various factors, including, but not limited to, the state of the financial markets for the Company's equity securities, the state of the commodity markets generally, variations in the nature, quality and quantity of any mineral deposits that may be located, variations in the market price of any mineral products the Company may produce or plan to produce, the inability of the Company to obtain any necessary permits, consents or authorizations required, including TSXV acceptance, for its planned activities, the inability of the Company to produce minerals from its properties successfully or profitably, to continue its projected growth, to raise the necessary capital or to be fully able to implement its business strategies, and other risks and uncertainties disclosed in the Company's latest interim Management Discussion and Analysis and filed with certain securities commissions in Canada. All of the Company's Canadian public disclosure filings may be accessed via and readers are urged to review these materials, including the technical reports filed with respect to the Company's mineral properties. To view the source version of this press release, please visit
Business Upturn
2 days ago
- Business Upturn
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
By Business Wire India Published on June 5, 2025, 14:15 IST Beijing, China: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice® fully human antibody platform family. It underscores the continued advancement of Biocytogen's comprehensive global patent strategy and highlights the innovation and international recognition of the company's proprietary technologies. RenMab™ mice are a core member of Biocytogen's independently developed RenMice® fully human antibody discovery platform family. Using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts. As a result, RenMab mice have the full repertoire of human antibody heavy chain VDJ and light chain VJ genes. It retains the ability to mount robust immune responses against diverse antigens, comparable to wild-type mice, and can generate fully human antibodies with native-like diversity, significantly improving the efficiency and success rate of discovering high-potential therapeutic candidates. Importantly, antibodies derived from RenMab mice require no additional humanization, effectively minimizing immunogenicity risks and streamlining the antibody drug development process. With distinct advantages in discovering fully human antibodies and TCRs with low immunogenicity, high diversity, favorable affinity, and excellent physicochemical properties, Biocytogen's RenMice platform series (RenMab™/RenLite®/RenNano®/RenTCR-mimic™/RenTCR™) has gained widespread recognition in the global biotech and biopharmaceutical industry. Licensing agreements have been established with 20+ companies, including Merck KGaA, Darmstadt, Germany, Janssen/ Johnson & Johnson, and BeiGene. Leveraging the RenMice platform, the RenBiologics™ program has generated over 1,000,000 fully human antibody sequences and numerous high-potential preclinical candidates against more than 1,000 therapeutic targets. As of December 31, 2024, approximately 200 agreements encompassing therapeutic antibody co-development, out-licensing, and asset transfers have been executed, highlighting the RenMice platform's strong global competitiveness and significant commercial value. With its sustained independent research and cutting-edge technological innovation capabilities, Biocytogen has been actively advancing its global patent portfolio and key technology protections for the RenMice® platform. To date, the RenMice platform has secured patent grants in nearly 10 countries, including the U.S., China, and Japan, while nearly 40 patent applications are under examination across 15 countries and regions. With the steady progress of the global patent strategy, additional patent grants are anticipated in the near term. This strong intellectual property protection framework will continue to deliver reliable assurance to Biocytogen's partners worldwide. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
